Oramed Pharmaceuticals Discloses 5% Activist Stake in Nano Dimension, Seeks Board Changes
NNDM sits 45% above its 52-week low of $1.31 on elevated volume (1.8× avg).
Summary
Oramed Pharmaceuticals Inc. and its CEO Nadav Kidron have acquired a 5.0% stake in Nano Dimension Ltd. for $18.25 million, declaring activist intentions including seeking changes to the board of directors.
Key Events · Ownership and Investor Activity · NNDM
-
New 5% Activist Stake Disclosed
Oramed Pharmaceuticals Inc. and its CEO Nadav Kidron have jointly filed a Schedule 13D, disclosing beneficial ownership of 10,549,430 Ordinary Shares, representing a 5.0% stake in Nano Dimension Ltd.
-
Substantial Investment Made
The Reporting Persons expended approximately $18.25 million to acquire these shares through various open market transactions, with funds primarily from Oramed's working capital and Mr. Kidron's personal funds.
-
Intent to Seek Board Changes
Oramed explicitly stated its intention to engage with Nano Dimension's management and board, including recommending changes to the composition of the board of directors, and discussing performance, strategy, and potential transactions.
Analysis · NNDM · Manufacturing
Oramed Pharmaceuticals Inc., led by its CEO Nadav Kidron, has disclosed a significant 5.0% stake in Nano Dimension Ltd., acquired through open market purchases totaling approximately $18.25 million. This filing signals an activist intent, as Oramed plans to engage with Nano Dimension's management and board to discuss performance, strategy, financing, and explicitly states an intention to recommend changes to the board's composition. This move introduces a new influential shareholder who may push for strategic shifts or operational improvements, potentially leading to governance changes or a re-evaluation of the company's direction. Investors should monitor future communications from Oramed and Nano Dimension's response to these activist demands.
At the time of this filing, NNDM was trading at $1.90 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $416.5M. The 52-week trading range was $1.31 to $2.69. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.